Julie K. Andersen mainly focuses on Substantia nigra, Oxidative stress, Parkinson's disease, Dopaminergic and Neurodegeneration. Julie K. Andersen interconnects Neurotoxicity and MPTP in the investigation of issues within Substantia nigra. Her Oxidative stress study integrates concerns from other disciplines, such as Mitochondrion and Cell biology.
As part of her studies on Parkinson's disease, Julie K. Andersen often connects relevant subjects like Neuroscience. Her Dopaminergic study is concerned with the field of Dopamine as a whole. Julie K. Andersen combines subjects such as Glutathione and Protein degradation with her study of Endocrinology.
Her scientific interests lie mostly in Oxidative stress, Parkinson's disease, Cell biology, Substantia nigra and Dopaminergic. Her Oxidative stress study combines topics in areas such as Alzheimer's disease and Molecular biology. Her Parkinson's disease study incorporates themes from Paraquat, Neurodegeneration and Pharmacology.
Her research in Cell biology intersects with topics in Calcium, Apoptosis, Programmed cell death and Caenorhabditis elegans. The concepts of her Substantia nigra study are interwoven with issues in Ferritin, Mitochondrion, MPTP and Neuroprotection. Her Dopaminergic study deals with Glutathione intersecting with Cysteine, Antioxidant and Protein degradation.
Julie K. Andersen mainly investigates Cell biology, Parkinson's disease, Pharmacology, Neurodegeneration and Neuroscience. Her studies in Cell biology integrate themes in fields like Autophagy, Regulator, Neurotoxin and Caenorhabditis elegans. She studies Parkinson's disease, namely Substantia nigra.
Her Substantia nigra study is associated with Dopaminergic. Julie K. Andersen has included themes like Glycogen synthase and MPTP in her Pharmacology study. Her Neuroscience research is multidisciplinary, incorporating elements of Parkin and Disease.
The scientist’s investigation covers issues in Cell biology, Neuroprotection, Substantia nigra, Pharmacology and Neurodegeneration. Her Cell biology study combines topics from a wide range of disciplines, such as Regulator, Biochemistry and Caenorhabditis elegans. Her study looks at the relationship between Neuroprotection and topics such as MPTP, which overlap with Agonist, Dopaminergic Cell, Downregulation and upregulation and Pars compacta.
Her Substantia nigra study is concerned with the larger field of Dopaminergic. As a part of the same scientific study, Julie K. Andersen usually deals with the Dopaminergic, concentrating on Parkinson's disease and frequently concerns with Lithium, Genetically modified mouse and Neuroscience. Her Pharmacology research is multidisciplinary, incorporating perspectives in Oxidative stress and Neurotoxicity.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Oxidative stress in neurodegeneration: cause or consequence?
Julie K Andersen.
Nature Medicine (2004)
Mice Deficient in Cellular Glutathione Peroxidase Show Increased Vulnerability to Malonate, 3-Nitropropionic Acid, and 1-Methyl-4-Phenyl-1,2,5,6-Tetrahydropyridine
Peter Klivenyi;Ole A. Andreassen;Robert J. Ferrante;Alpaslan Dedeoglu.
The Journal of Neuroscience (2000)
Genetic or Pharmacological Iron Chelation Prevents MPTP-Induced Neurotoxicity In Vivo: A Novel Therapy for Parkinson's Disease
Deepinder Kaur;Ferda Yantiri;Subramanian Rajagopalan;Jyothi Kumar.
Neuron (2003)
Glutathione, iron and Parkinson’s disease
Srinivas Bharath;Michael Hsu;Deepinder Kaur;Subramanian Rajagopalan.
Biochemical Pharmacology (2002)
Cellular senescence: a link between cancer and age-related degenerative disease?
Judith Campisi;Julie K. Andersen;Pankaj Kapahi;Simon Melov.
Seminars in Cancer Biology (2011)
Mitochondrial alpha-synuclein accumulation impairs complex I function in dopaminergic neurons and results in increased mitophagy in vivo
Shankar J. Chinta;Jyothi K. Mallajosyula;Anand Rane;Julie K. Andersen.
Neuroscience Letters (2010)
Caspase-9 activation results in downstream caspase-8 activation and bid cleavage in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease.
Veena Viswanath;Yongqin Wu;Rapee Boonplueang;Rapee Boonplueang;Sylvia Chen.
The Journal of Neuroscience (2001)
Redox imbalance in Parkinson's disease
Shankar J. Chinta;Julie K. Andersen.
Biochimica et Biophysica Acta (2008)
Glutathione Depletion in PC12 Results in Selective Inhibition of Mitochondrial Complex I Activity IMPLICATIONS FOR PARKINSON′S DISEASE
Nandita Jha;Octavian Jurma;Giovanna Lalli;Yi Liu.
Journal of Biological Chemistry (2000)
Cognitive efficiency on a match to sample task decreases at the onset of puberty in children.
Robert F McGivern;Julie Andersen;Desiree Byrd;Kandis L Mutter.
Brain and Cognition (2002)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:
Buck Institute for Research on Aging
Harvard University
Buck Institute for Research on Aging
Harvard University
Cornell University
Buck Institute for Research on Aging
Buck Institute for Research on Aging
Buck Institute for Research on Aging
Buck Institute for Research on Aging
University of California, Los Angeles
Al-Azhar University – Gaza
University of Queensland
Université Paris Cité
Pohang University of Science and Technology
University of Michigan–Ann Arbor
Zhejiang University
Oregon Health & Science University
John Innes Centre
Washington University in St. Louis
University of California, Davis
National Institutes of Health
University of Oxford
Georgetown University
RWTH Aachen University
Australian National University
Leiden University